Eli Lilly shares rise 2.1% on analyst upgrades; MercadoLibre to report Q2 2026 earnings; Elicio Therapeutics forecasts a
Eli Lilly & Co. (NYSE: LLY) shares increased 2.1% on Tuesday, reaching a high of $1,232.00 and closing at $1,222.61. Several analysts raised their price targets, with Citigroup moving its objective to $1,600, Barclays to $1,400, and other firms issuing buy or overweight ratings.
MercadoLibre, Inc. announced that it will publish its second‑quarter 2026 financial results on August 5, 2026, and will hold a video conference and call at 5:00 p.m. Eastern Time for investors and analysts.
Elicio Therapeutics (NASDAQ: ELTX) expects to report Q2 2026 earnings per share of –$0.53. The company previously posted EPS of –$0.65, missing the consensus estimate of –$0.49. Its market capitalization is about $55.2 million with a PE ratio of –1.20.
Entities: Elevance Health Inc. · Eli Lilly and Company · Elicio Therapeutics · Excelsior Advisor Network LLC · MercadoLibre, Inc. · Ruane Cunniff & Goldfarb L.P. · Tesla Inc.
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] Elicio Therapeutics previously reported EPS of –$0.65, missing consensus estimate of –$0.49. (source)
- [○ 1 SOURCE] Citigroup raised its price objective for Eli Lilly from $1,500 to $1,600 and gave a buy rating. (source)
- [○ 1 SOURCE] Elicio Therapeutics has a market cap of $55.17 million and a PE ratio of –1.20. (source)
- [○ 1 SOURCE] Elicio Therapeutics expects Q2 2026 earnings per share of –$0.53. (source)
- [○ 1 SOURCE] MercadoLibre will host a video conference and call at 5:00 p.m. Eastern Time on August 5, 2026. (source)
- [○ 1 SOURCE] Eli Lilly shares rose 2.1% on Tuesday, reaching $1,232.00 and closing at $1,222.61. (source)
- [○ 1 SOURCE] Barclays lifted its price target for Eli Lilly from $1,350 to $1,400 and issued an overweight rating. (source)
- [○ 1 SOURCE] MercadoLibre will release its Q2 2026 financial results on August 5, 2026. (source)